Emma Walmsley, GSK CEO
June 6, 2023 11:03 AM EDT
People

Ex­clu­sive: GSK CEO Em­ma Walm­s­ley talks about vac­cines, M&A and the com­pa­ny’s fu­ture

Drew Armstrong

Executive Editor

British drug gi­ant GSK is at an in­flec­tion point. The com­pa­ny shed its con­sumer unit Ha­le­on and plans to put the pro­ceeds in­to build­ing out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times